Tenet Healthcare Corporation (THC)
NYSE: THC · Real-Time Price · USD
242.88
+7.76 (3.30%)
Mar 3, 2026, 4:00 PM EST - Market closed
Tenet Healthcare Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Tenet Healthcare stock have an average target of 235.3, with a low estimate of 154 and a high estimate of 288. The average target predicts a decrease of -3.12% from the current stock price of 242.88.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Tenet Healthcare stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 6 | 7 |
| Buy | 10 | 10 | 10 | 10 | 10 | 11 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 18 | 18 | 19 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $255 → $264 | Buy | Maintains | $255 → $264 | +8.70% | Feb 20, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $240 → $270 | Strong Buy | Maintains | $240 → $270 | +11.17% | Feb 17, 2026 |
| Barclays | Barclays | Buy Maintains $240 → $257 | Buy | Maintains | $240 → $257 | +5.81% | Feb 13, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $257 → $271 | Strong Buy | Maintains | $257 → $271 | +11.58% | Feb 13, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $250 → $265 | Strong Buy | Maintains | $250 → $265 | +9.11% | Feb 12, 2026 |
Financial Forecast
Revenue This Year
22.33B
from 21.31B
Increased by 4.80%
Revenue Next Year
22.88B
from 22.33B
Increased by 2.44%
EPS This Year
16.61
from 15.49
Increased by 7.21%
EPS Next Year
17.97
from 16.61
Increased by 8.19%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 24.1B | 24.9B | |||
| Avg | 22.3B | 22.9B | |||
| Low | 21.4B | 21.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 13.3% | 11.6% | |||
| Avg | 4.8% | 2.4% | |||
| Low | 0.4% | -5.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.69 | 21.26 | |||
| Avg | 16.61 | 17.97 | |||
| Low | 13.92 | 13.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 20.7% | 28.0% | |||
| Avg | 7.2% | 8.2% | |||
| Low | -10.2% | -15.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.